PubRank

W J Sandborn

Author PubWeight™ 156.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000 6.90
2 Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011 5.44
3 Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998 4.52
4 The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002 3.71
5 The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 3.60
6 Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000 2.86
7 Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001 2.80
8 Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther 2015 2.25
9 PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005 2.22
10 Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2010 2.20
11 Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009 2.20
12 A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014 2.18
13 Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999 2.14
14 Mycophenolate mofetil for Crohn's disease? Lancet 1999 2.03
15 Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013 1.99
16 Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005 1.96
17 Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum 1999 1.79
18 Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008 1.75
19 Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000 1.71
20 Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013 1.69
21 Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013 1.63
22 Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999 1.61
23 Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2014 1.56
24 Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999 1.56
25 Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000 1.56
26 Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009 1.54
27 Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995 1.54
28 MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut 2009 1.53
29 Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996 1.47
30 A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001 1.47
31 Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000 1.46
32 Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001 1.46
33 Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996 1.46
34 Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr 1998 1.44
35 Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol 2000 1.42
36 Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998 1.39
37 Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999 1.38
38 Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis 1999 1.36
39 Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996 1.33
40 Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006 1.32
41 Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013 1.32
42 Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001 1.30
43 Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007 1.28
44 Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol 2001 1.27
45 Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007 1.25
46 Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006 1.25
47 Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001 1.24
48 Crohn's disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis 2001 1.24
49 Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006 1.18
50 Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010 1.18
51 Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2012 1.15
52 Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005 1.13
53 Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001 1.12
54 Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001 1.11
55 Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001 1.10
56 MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008 1.10
57 Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol 1995 1.09
58 Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998 1.09
59 Systematic review: the management of pouchitis. Aliment Pharmacol Ther 2006 1.08
60 Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2010 1.07
61 Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc 2005 1.05
62 Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999 1.05
63 Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther 1997 1.01
64 Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001 1.01
65 Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001 1.01
66 Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol 2001 0.99
67 The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002 0.99
68 Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 1997 0.98
69 Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc 1999 0.98
70 Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther 2001 0.96
71 Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther 2009 0.95
72 Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer 1998 0.95
73 Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther 2007 0.94
74 Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012 0.93
75 Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther 2012 0.93
76 CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging 2009 0.93
77 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996 0.93
78 Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997 0.91
79 Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008 0.90
80 Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011 0.90
81 Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis 2000 0.90
82 Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol 1995 0.89
83 Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998 0.89
84 A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2014 0.88
85 Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 1997 0.87
86 Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999 0.87
87 A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999 0.86
88 Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011 0.86
89 Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005 0.86
90 Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther 1997 0.86
91 Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology 2000 0.86
92 Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J Clin Pharmacol 1997 0.86
93 Cyclosporin for refractory ulcerative colitis. Gut 2003 0.85
94 Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010 0.84
95 A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther 1997 0.84
96 Nicotine carbomer enemas--pharmacokinetics of a revised formulation. Ital J Gastroenterol Hepatol 1998 0.83
97 The appendix in ulcerative colitis: a not so innocent bystander. Gastroenterology 1999 0.82
98 Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis 1999 0.82
99 Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum 1997 0.81
100 Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 1999 0.81
101 Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther 1999 0.80
102 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology 1997 0.80
103 Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl 2001 0.80
104 Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 2001 0.79
105 CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006 0.79
106 Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther 2014 0.79
107 The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. Aliment Pharmacol Ther 2010 0.78
108 A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol 1997 0.78
109 A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology 1997 0.78
110 A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005 0.78
111 Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis 1999 0.77
112 Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? Gastroenterology 1998 0.77
113 Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 1998 0.77
114 Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology 1998 0.77
115 A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001 0.77
116 Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc 1999 0.77
117 Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology 1999 0.77
118 Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis 1999 0.76
119 European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut 2007 0.76
120 Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum 1999 0.75
121 Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis 2000 0.75
122 Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology 1998 0.75
123 Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc 1997 0.75
124 Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther 1998 0.75
125 Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996 0.75
126 Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? Gastroenterology 1998 0.75
127 Drug therapy for inflammatory bowel disease. Contemp Intern Med 1995 0.75
128 A comparison of budesonide and mesalamine for active Crohn's disease. Gastroenterology 1999 0.75
129 Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep 2001 0.75
130 A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology 1997 0.75